Anika Therapeutics (ANIK) Current Deferred Revenue (2010 - 2026)

Anika Therapeutics (ANIK) reported Current Deferred Revenue of $229000.0 for Q1 2026, up 340.38% quarter-over-quarter from $52000.0 in Q3 2018.

Anika Therapeutics (ANIK) Current Deferred Revenue (2010 - 2026) Analysis & Trends

Anika Therapeutics (ANIK) has 8 years of Current Deferred Revenue data on file, last reported at $229000.0 in Q1 2026.

Current Deferred Revenue for Q1 2026 came in at $229000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $229000.0 (changed N/A YoY), and the FY2014 annual result was $24510.0, down 98.9% from the prior year.
Current Deferred Revenue advanced to $229000.0 in Q1 2026 per ANIK's latest filing, from $52000.0 in the prior quarter.
Over five years, Current Deferred Revenue peaked at $229000.0 in Q1 2026 and troughed at $229000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn
10	Anika Therapeutics	197.89 Mn	131.10 Mn	19.00 Mn

Download Data